Scotland Okays Funding For Keytruda and Opdivo For Esophageal Cancer, Among Other Drugs
Executive Summary
Immunotherapies for esophageal cancer from BMS and MSD are among the medicines that Scotland’s health technology appraisal body has recommended for use on the National Health Service.
You may also be interested in...
European HTAs And Payers On How To Tackle The Evidence Problem
European payers and health technology appraisal organizations have warned that their decision making is being increasingly hampered by evidence gaps. Some solutions may lie in the better use of existing mechanisms, such as scientific advice and managed entry agreements, while others could be introduced through the overhaul of the EU pharmaceutical legislation.
Health System Reform Crucial For ATMPs
The difficulties in getting advanced therapies, such as Novartis’ CAR T therapy Kymriah, to patients have shifted and manufacturing capacity is no longer the biggest issue.
Payer Wish List For EU Pharma Legislation – Is The European Commission Listening?
At a recent webinar payers and health technology appraisal bodies gave further details on what they want included and left out of the European Commission’s overhaul of the EU pharmaceutical legislation. However, speakers voiced some concerns about whether their demands will be met.